Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC
Janne Selke, Yvonne Dzierma, Katrin Manda, Guido Hildebrandt, Bernd Frerker, Paul Kalata, Christin Ackermann, Felix Bock · 2026
Read Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC by Janne Selke, Yvonne Dzierma, Katrin Manda, Guido Hildebrandt, Bernd Frerker, Paul Kalata, Christin Ackermann, Felix Bock (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13297644.txt.
Description
Routine practice backs consolidation immunotherapy after chemoradiation for advanced lung cancer, at least when tumors express PD-L1. Janne Selke and colleagues present real-world survival data in 2026 for people with unresectable stage III non-small cell lung cancer, comparing outcomes with and without durvalumab.
Patients whose tumors were PD-L1 positive and who received durvalumab lived significantly longer, both overall and without progression, than comparable patients treated without it. PD-L1-positive patients who never got the drug fared worst of all. The authors read the pattern as support for the treatment's value outside trials, and as a reminder that PD-L1 testing and actual access to consolidation therapy shape survival.
Catalog record
| CREATOR | Janne Selke, Yvonne Dzierma, Katrin Manda, Guido Hildebrandt, Bernd Frerker, Paul Kalata, Christin Ackermann, Felix Bock |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29455 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |